CN112029865A - Probe group and gene chip for simultaneously detecting multiple gene mutation types and application thereof - Google Patents
Probe group and gene chip for simultaneously detecting multiple gene mutation types and application thereof Download PDFInfo
- Publication number
- CN112029865A CN112029865A CN202010991893.6A CN202010991893A CN112029865A CN 112029865 A CN112029865 A CN 112029865A CN 202010991893 A CN202010991893 A CN 202010991893A CN 112029865 A CN112029865 A CN 112029865A
- Authority
- CN
- China
- Prior art keywords
- gene
- ret
- dna
- ros1
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 title claims abstract description 86
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 69
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 31
- 230000035772 mutation Effects 0.000 claims abstract description 42
- 238000001514 detection method Methods 0.000 claims abstract description 26
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims abstract description 15
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims abstract description 15
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims abstract description 10
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims abstract description 10
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims abstract description 9
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims abstract description 9
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims abstract description 8
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims abstract description 8
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims abstract description 7
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims abstract description 7
- 102100029166 NT-3 growth factor receptor Human genes 0.000 claims abstract description 7
- 108010064892 trkC Receptor Proteins 0.000 claims abstract description 7
- 101150105382 MET gene Proteins 0.000 claims abstract description 6
- 108020004414 DNA Proteins 0.000 claims description 59
- 238000012163 sequencing technique Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 15
- -1 MET Proteins 0.000 claims description 13
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 238000010276 construction Methods 0.000 claims description 6
- 102220101909 rs878854850 Human genes 0.000 claims description 6
- 238000007400 DNA extraction Methods 0.000 claims description 5
- 102100030708 GTPase KRas Human genes 0.000 claims description 5
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 5
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 5
- 102100031077 Calcineurin B homologous protein 3 Human genes 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 102100038595 Estrogen receptor Human genes 0.000 claims description 4
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims description 4
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 4
- 229940044683 chemotherapy drug Drugs 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 claims description 3
- 101150023956 ALK gene Proteins 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 3
- 101150039808 Egfr gene Proteins 0.000 claims description 3
- 102100039788 GTPase NRas Human genes 0.000 claims description 3
- 101150054472 HER2 gene Proteins 0.000 claims description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 3
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 3
- 101150105104 Kras gene Proteins 0.000 claims description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 3
- 101150077555 Ret gene Proteins 0.000 claims description 3
- 101150035397 Ros1 gene Proteins 0.000 claims description 3
- 101150048834 braF gene Proteins 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 108700021358 erbB-1 Genes Proteins 0.000 claims description 3
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 102220198013 rs1057519824 Human genes 0.000 claims description 3
- 102220198453 rs1057520030 Human genes 0.000 claims description 3
- 102220004855 rs121913243 Human genes 0.000 claims description 3
- 102220197908 rs121913244 Human genes 0.000 claims description 3
- 102220197954 rs121913245 Human genes 0.000 claims description 3
- 102220004853 rs121913246 Human genes 0.000 claims description 3
- 102220054859 rs727502902 Human genes 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 claims description 2
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims description 2
- 102000000872 ATM Human genes 0.000 claims description 2
- 102100037129 ATP-binding cassette sub-family C member 11 Human genes 0.000 claims description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 2
- 102100029361 Aromatase Human genes 0.000 claims description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 2
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims description 2
- 101710098191 C-4 methylsterol oxidase ERG25 Proteins 0.000 claims description 2
- 101710147325 Calcineurin B homologous protein 3 Proteins 0.000 claims description 2
- 102100035249 Carbonyl reductase [NADPH] 3 Human genes 0.000 claims description 2
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 2
- 102100033187 Centrosomal protein of 72 kDa Human genes 0.000 claims description 2
- 101710202346 Centrosomal protein of 72 kDa Proteins 0.000 claims description 2
- 102100024206 Collectin-10 Human genes 0.000 claims description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 2
- 102100026846 Cytidine deaminase Human genes 0.000 claims description 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims description 2
- 102100037147 Cytoplasmic dynein 2 heavy chain 1 Human genes 0.000 claims description 2
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 claims description 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims description 2
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims description 2
- 101100226017 Dictyostelium discoideum repD gene Proteins 0.000 claims description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 2
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 claims description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims description 2
- 102100023471 E-selectin Human genes 0.000 claims description 2
- 101150105460 ERCC2 gene Proteins 0.000 claims description 2
- 102100021469 Equilibrative nucleoside transporter 1 Human genes 0.000 claims description 2
- 102100029951 Estrogen receptor beta Human genes 0.000 claims description 2
- 102000036353 FBXWs Human genes 0.000 claims description 2
- 108091007023 FBXWs Proteins 0.000 claims description 2
- 108091008794 FGF receptors Proteins 0.000 claims description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 102100029974 GTPase HRas Human genes 0.000 claims description 2
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 claims description 2
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims description 2
- 102100023541 Glutathione S-transferase omega-1 Human genes 0.000 claims description 2
- 101000783609 Homo sapiens 5-hydroxytryptamine receptor 1E Proteins 0.000 claims description 2
- 101001029057 Homo sapiens ATP-binding cassette sub-family C member 11 Proteins 0.000 claims description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 2
- 101000919395 Homo sapiens Aromatase Proteins 0.000 claims description 2
- 101000737274 Homo sapiens Carbonyl reductase [NADPH] 3 Proteins 0.000 claims description 2
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 2
- 101000909632 Homo sapiens Collectin-10 Proteins 0.000 claims description 2
- 101000881344 Homo sapiens Cytoplasmic dynein 2 heavy chain 1 Proteins 0.000 claims description 2
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 claims description 2
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims description 2
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims description 2
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 claims description 2
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 claims description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 2
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims description 2
- 101000906386 Homo sapiens Glutathione S-transferase omega-1 Proteins 0.000 claims description 2
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims description 2
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 2
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims description 2
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 claims description 2
- 101000603239 Homo sapiens Neuroligin-1 Proteins 0.000 claims description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 2
- 101000632266 Homo sapiens Semaphorin-3C Proteins 0.000 claims description 2
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims description 2
- 101000835995 Homo sapiens Slit homolog 1 protein Proteins 0.000 claims description 2
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 claims description 2
- 101000831940 Homo sapiens Stathmin Proteins 0.000 claims description 2
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 claims description 2
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 2
- 101000914628 Homo sapiens Uncharacterized protein C8orf34 Proteins 0.000 claims description 2
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims description 2
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 2
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 claims description 2
- 229910015837 MSH2 Inorganic materials 0.000 claims description 2
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims description 2
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims description 2
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 claims description 2
- 101150097381 Mtor gene Proteins 0.000 claims description 2
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims description 2
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims description 2
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims description 2
- 102000007530 Neurofibromin 1 Human genes 0.000 claims description 2
- 108010085793 Neurofibromin 1 Proteins 0.000 claims description 2
- 102100038992 Neuroligin-1 Human genes 0.000 claims description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 2
- 108010065129 Patched-1 Receptor Proteins 0.000 claims description 2
- 102000012850 Patched-1 Receptor Human genes 0.000 claims description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 claims description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 2
- 108091006531 SLC28A3 Proteins 0.000 claims description 2
- 108091006551 SLC29A1 Proteins 0.000 claims description 2
- 102000001332 SRC Human genes 0.000 claims description 2
- 108060006706 SRC Proteins 0.000 claims description 2
- 102100027980 Semaphorin-3C Human genes 0.000 claims description 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 2
- 102100025490 Slit homolog 1 protein Human genes 0.000 claims description 2
- 102000013380 Smoothened Receptor Human genes 0.000 claims description 2
- 101710090597 Smoothened homolog Proteins 0.000 claims description 2
- 102100021470 Solute carrier family 28 member 3 Human genes 0.000 claims description 2
- 102100024237 Stathmin Human genes 0.000 claims description 2
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims description 2
- 102100038618 Thymidylate synthase Human genes 0.000 claims description 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 2
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 claims description 2
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims description 2
- 102100027225 Uncharacterized protein C8orf34 Human genes 0.000 claims description 2
- 102000002258 X-ray Repair Cross Complementing Protein 1 Human genes 0.000 claims description 2
- 108010000443 X-ray Repair Cross Complementing Protein 1 Proteins 0.000 claims description 2
- 108700031763 Xeroderma Pigmentosum Group D Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 108010045815 superoxide dismutase 2 Proteins 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 230000004927 fusion Effects 0.000 abstract description 19
- 238000012217 deletion Methods 0.000 abstract description 6
- 230000037430 deletion Effects 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 description 17
- 239000011324 bead Substances 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 235000017003 Cissus Nutrition 0.000 description 1
- 244000035145 Cissus repens Species 0.000 description 1
- 235000017014 Cissus repens Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 102100022477 DNA repair protein complementing XP-C cells Human genes 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100021023 Gamma-glutamyl hydrolase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 1
- 101000618535 Homo sapiens DNA repair protein complementing XP-C cells Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101000807596 Homo sapiens Orotidine 5'-phosphate decarboxylase Proteins 0.000 description 1
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000040856 WT1 Human genes 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- 101150084041 WT1 gene Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 208000037967 hot tumor Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102200048928 rs121434568 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940127072 targeted antineoplastic agent Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of gene detection, and particularly relates to a probe set for simultaneously detecting multiple gene mutation types. The invention can detect mutation of up to 102 genes at one time, thereby finding known and/or unknown mutation; the invention can detect related rare hotspot variation, namely 14 exon skipping mutation of MET gene, BCL2L11(BIM)2 intron deletion polymorphism related region and NTRK1/2/3 hotspot fusion mutation at one time; the invention can detect known hot spot fusion variation and unknown fusion variation of 6 genes-ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 of specific fusion breakpoint regions more sensitively (0.5%).
Description
Technical Field
The invention belongs to the technical field of gene detection, and particularly relates to a probe set for simultaneously detecting multiple gene mutation types and application thereof.
Background
According to the World Health Organization (WHO) statistics, about 60% of people die from cancer, diabetes, cardiovascular disease, chronic respiratory disease, 4 major causes of death in the world. In 2015, about 392.9 ten thousand people suffer from Chinese malignant tumor, and about 233.8 ten thousand people die. On average, over 1 million people per day were diagnosed with cancer, and 7.5 people per minute were diagnosed with cancer. In recent decades, the onset and death of malignant tumors have been rising, and the medical cost of malignant tumors is over 2200 billion per year (Chen, W., et al., Cancer standards in China, 2015.CA Cancer J Clin, 2016.66 (2): p.115-32).
The development and development of tumors is a complex process involving multiple factors, multiple steps, and multiple genes. The research of tumor genetics reveals nearly 140 driving genes, and the common genes are: EGFR, KRAS, EML4-ALK, BRAF, PI3KCA, AKT1, MEK1, MET, HER2, RET, NRAS, and NTRK1, etc., which are distributed in 12 signaling pathways and regulate cell proliferation, apoptosis, and cell differentiation, respectively (Vogelstein, B., et al, Cancer gene landscapes. science, 2013.339 (6127): p.1546-58).
In the beginning of 2015, the global system of the united states, oarbama, officially started an 'accurate medical plan' in the statement of national consultancy, the current tumor treatment is gradually changed from the treatment of 'symptoms' to the treatment of 'genes', and appropriate targeted drugs are pertinently selected through mutation detection of related driving genes, so that individualized medical treatment is realized, and the optimal treatment effect of patients is achieved. By 2016, 72 targeted antineoplastic drugs were approved by the U.S. Food and Drug Administration (FDA). However, detection of tumor-driving genes is not straightforward. On one hand, the types of molecular targets involved are complex, including point mutation, short fragment insertion deletion, copy number variation, fusion gene and the like, and the omission of mutation types of related targets greatly reduces the targeted medication guidance of patients. On the other hand, tissue samples of patients with advanced tumors are difficult to obtain, and ctDNA (Cell-free Circulating Tumor DNA) detection is noninvasive, but due to the presence of a large amount of normal tissue free DNA, the ctDNA content is usually between 1% and 0.01% of ultralow frequency, and the precision detection is difficult. Currently, the most common technical method for detecting the driver gene is RT-PCR technology, and although the method is simple and rapid, the method has the limitations that only known mutation sites can be detected, the detected mutation types are not complete, the sensitivity is low (about 1 percent), and the like. The currently accepted gene mutation detection standard in the industry is a Sanger sequencing method, and the technology has the advantages of complex operation, low flux, low sensitivity (10%), high detection leakage risk and difficulty in meeting the detection requirements of a large number of tumor patients.
Therefore, there is a need in the art for a new technology that is comprehensive, highly sensitive, high-throughput, and simultaneously and precisely detects multiple mutation types, so as to effectively complement and improve the existing tumor personalized diagnosis and treatment.
Disclosure of Invention
As described above, there is a need in the art for a new technique that is comprehensive, highly sensitive, high-throughput, and simultaneously accurate for the detection of multiple mutation types.
Accordingly, in a first aspect, the present invention provides a probe set for simultaneously detecting multiple gene mutation types, the probe set comprising a probe for a targeted medication-related gene, wherein the targeted medication-related gene comprises EGFR, BRAF, KRAS, HER2, MET, ALK, RET, ROS1, NTRK1, NTRK2, NTRK3, and gene mutations thereon comprise:
1) for the EGFR gene: g719, A698, V765, F712, L703, A702, G724, E709, S720, E709, S752_ I759del, L747_ S752del, L747_ T751del, E746_ A750del, E746_ S752> 747_ E749del, L747_ T751> 746_ E749del, K745_ E749del, L747_ T751del, S752_ I759del, T751_ I759del, L747_ P753> 746_ S752del, E _ T751del, E746_ T746 > 871 _ T871, G779D 793, G793D 793, G79779, G793D 770, G793D 770, 3D 793D 79, G793D 79, D793, D793D 79, D769, 3D 770, 3D 793D 79, 3D 793, 3D 79, K752 > 751, 3D 793D 7944, 3D 7944, 3D 770, 3D 7944, 3D 7944, 3D 78, 3D 7944, 3D 7944, 3D 793, 3D 79;
2) for the BRAF gene: a598_ T599insV, a598V, D594G, D594N, D594V, E586E, E586K, F583F, F595L, F595S, G596D, G596R, G606E, H608R, I582M, I592M, I592V, K601V, L584V, L597V, N593672, P213V, S605V, S V, T599_ V600insT, T599_ V600insTT, T599V, V600_ K601 593672 > V, V600, V36600, V600V V, V36600V V, V;
3) for the KRAS gene: g _ a11insG, G13insG, L19, G13, V14, G12, L19, G _ V14insG, G12, V8, a11, G12, G13, G15, a18, Q22, G13, a _ G12insG, a59, Q61, T58, a146, K117;
4) for the HER2 gene: D769H, L755S, I767M, L755P, G776> VC, V777L, G776V, G778_ S779insG, V777A, V842I, H878Y;
5) for the MET gene: exon skipping mutations of E168D, T1010I, H1112Y, H1124D, H1112L, L1130L, N1118Y, H1112R, M1268T, Y1248C, Y1253D, 14;
6) for the ALK gene: EML 4-ALK;
7) for the RET gene: NCOA4-RET, PRKAR1A-RET, PCM1-RET, KTN1-RET, KIF5B-RET, HOOK3-RET, GOLGA5-RET, CCDC 6-RET;
8) for the ROS1 gene: TPM3-ROS1, SLC34A2-ROS1, SDC4-ROS1, LRIG3-ROS1, GOPC-ROS1, EZR-ROS1, CD74-ROS 1;
9) for NTRK1/2/3 genes: TPM3-NTRK1, LMNA-NTRK1, NACC2-NTRK2, QKI-NTRK2, ETV6-NTRK 3.
In a second aspect, the present invention provides a gene chip for simultaneously detecting a plurality of gene mutation types, the gene chip comprising the probe set of the first aspect of the present invention.
In a third aspect, the present invention provides a method for detecting multiple types of gene mutations, the method comprising the steps of:
1) designing a probe: designing and synthesizing a probe set according to the first aspect of the invention;
2) DNA extraction and disruption: extracting DNA of a sample to be detected and breaking the DNA into DNA fragments of 200-250 bp;
3) library construction: constructing a sample library using the disrupted DNA;
4) and (3) hybridization and capture: contacting the sample library of step 3) with the probe set of step 1) for hybrid capture;
5) and (3) machine sequencing: sequencing the captured sequence obtained in step 4) to generate sequencing data;
6) information analysis: analyzing and annotating gene mutation information of the sequencing data obtained in the step 5).
In a fourth aspect, the present invention provides a kit for simultaneously detecting a plurality of gene mutation types, the kit comprising the probe set of the first aspect of the present invention or the gene chip of the second aspect of the present invention.
In a fifth aspect, the present invention provides the use of a probe set according to the first aspect of the present invention or a gene chip according to the second aspect of the present invention in the preparation of a detection reagent for simultaneously detecting one or more types of gene mutations.
The invention has the beneficial effects that:
(1) the invention can realize one-time simultaneous detection of gene mutations of 102 tumor driving genes including EGFR, KRAS, BRAF, c-MET, HER2, ALK, ROS1, RET, NTRK1/2/3 and the like, including point mutation, short fragment insertion deletion, copy number variation and gene fusion;
(2) the invention can detect the known mutation of the probe coverage area and can discover new unknown variation at the same time;
(3) the invention can detect related rare hotspot variation, namely 14 exon skipping mutation of MET gene, BCL2L11(BIM)2 intron deletion polymorphism related region and NTRK1/2/3 hotspot fusion mutation at one time;
(4) aiming at 6 genes-ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 of specific fusion breakpoint regions, the invention performs three times of high probe abundance coverage on the genes, so that the known hot spot fusion and unknown fusion variation of the genes can be detected more sensitively (0.5 percent);
(5) the invention is suitable for paraffin embedded tissues or paraffin sections, fresh pathological tissues, blood plasma, hydrothorax, ascites, cerebrospinal fluid and other sample types;
(6) the invention provides a detection method capable of simultaneously providing targeted medication and chemotherapy medication guidance.
Drawings
FIG. 1 is a flow chart of the present invention.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments. It will be understood by those skilled in the art that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. The described embodiments are only a few embodiments of the invention, not all embodiments. All other embodiments are available to the person skilled in the art based on the embodiments of the invention and are within the scope of protection of the invention.
In the present specification and claims, when referring to a gene sequence, it will be understood by those skilled in the art that the gene sequence actually includes either or both of the complementary double strands. For convenience, in the present specification and claims, although only one strand is given in most cases, the other strand complementary thereto is actually disclosed. For example, reference to a probe sequence actually includes the sequence and its complement. For example, reference is made to SEQ ID NO:1, actually including its complement. One skilled in the art will also appreciate that one strand may be used to detect the other strand and vice versa.
The gene sequence in the present invention includes a DNA form or an RNA form, and in the case where one is disclosed, it means that the other is also disclosed. For example, reference to a probe sequence actually includes the corresponding RNA sequence.
As described above, there is a need in the art for a new technique that is comprehensive, highly sensitive, high-throughput, and simultaneously accurate for the detection of multiple mutation types.
The present invention provides a set of probes for simultaneously detecting multiple gene mutation types. The design length of the probe is 60-150nt, such as 120nt, and 100% coverage of a target area and at least more than 60% of high-specificity capture effect can be achieved through precise calculation. The designed probe is synthesized by the relevant synthesis companies such as IDT or Roche. A sample library is subjected to hybridization capture by adopting the enrichment probe designed by the invention, a corresponding sequencing platform is selected to carry out PE150 sequencing according to linker sequences (Illumina platform or Huada intelligent sequencing platform) of different sequencing platforms adopted during library construction, obtained sequencing data are obtained, then a single sample sequencing information analysis process is carried out, and effective mutation of a target medication related gene and a base type of a chemotherapy medication related gene are obtained, so that personalized medication guidance is carried out.
In the invention, the design of the probe aiming at the gene related to the targeted medication is based on databases such as TCGA, ICGC, COSMIC and the like and related literature references, and covers the comprehensive mutation sites of the hot tumor driving genes of common tumors such as lung cancer, colorectal cancer, gastric cancer, breast cancer, kidney cancer, pancreatic cancer, ovarian cancer, endometrial cancer, thyroid cancer, cervical cancer, esophageal cancer, liver cancer and the like, including point mutation, short fragment insertion deletion, copy number variation and fusion genes, and the total of 5727 hot point mutations.
Accordingly, in a first aspect, the present invention provides a probe set for simultaneously detecting multiple gene mutation types, the probe set comprising a probe for a targeted medication-related gene, wherein the targeted medication-related gene comprises EGFR, BRAF, KRAS, HER2, MET, ALK, RET, ROS1, NTRK1, NTRK2, NTRK3, and a gene mutation thereon comprises:
1) for the EGFR gene: g719, A698, V765, F712, L703, A702, G724, E709, S720, E709, S752_ I759del, L747_ S752del, L747_ T751del, E746_ A750del, E746_ S752> 747_ E749del, L747_ T751> 746_ E749del, K745_ E749del, L747_ T751del, S752_1759del, T751_ I759del, L747_ P753> 746_ S752del, E _ T751del, E746_ T751> 746_ T871, S752_ S747 _ T747 del, E _ T751> 746_ D779, G793D 793, G793D 79, G793D 770, GI 79858, GI 793, GI 779, GI 793, GI;
2) for the BRAF gene: a598_ T599insV, a598V, D594G, D594N, D594V, E586E, E586K, F583F, F595L, F595S, G596D, G596R, G606E, H608R, I582M, I592M, I592V, K601V, L584V, L597V, N593672, P213V, S605V, S V, T599_ V600insT, T599_ V600insTT, T599V, V600_ K601 593672 > V, V600, V36600, V600V V, V36600V V, V;
3) for the KRAS gene: g _ a11insG, G12G13insG, L19, G13, V14, G12, L19, G _ V14insG, G12, V8, a11, G12, G13, G15, a18, Q22, G13, a _ G12insGA, a59, Q61, T58, a146, K117;
4) for the HER2 gene: D769H, L755S, I767M, L755P, G776> VC, V777L, G776V, G778_ S779insG, V777A, V842I, H878Y;
5) for the MET gene: exon skipping mutations of E168D, T1010I, H1112Y, H1124D, H1112L, L1130L, N1118Y, H1112R, M1268T, Y1248C, Y1253D, 14;
6) for the ALK gene: EML 4-ALK;
7) for the RET gene: NCOA4-RET, PRKAR1A-RET, PCM1-RET, KTN1-RET, KIF5B-RET, HOOK3-RET, GOLGA5-RET, CCDC 6-RET;
8) for the ROS1 gene: TPM3-ROS1, SLC34A2-ROS1, SDC4-ROS1, LRIG3-ROS1, GOPC-ROS1, EZR-ROS1, CD74-ROS 1;
9) for NTRK1/2/3 genes: TPM3-NTRK1, LMNA-NTRK1, NACC2-NTRK2, QKI-NTRK2, ETV6-NTRK 3.
It is to be noted that in the present invention, the positions of the genes referred to above are based on the COSMIC database. However, one skilled in the art will appreciate that such genomic locations may correspond to locations of other versions of genomic data, as long as the relative locations of the genes correspond. In the present invention, mutations are expressed by a common expression in the art. For example, the mutations G719C and G719S indicate a mutation of glycine G at position 719 to cysteine C and serine S, respectively.
As will be appreciated by those skilled in the art, more accurate detection results can be obtained for a gene mutation with a relatively large number of probes. However, from the viewpoint of adverse interactions that may occur between the probes with each other and from the economical viewpoint, a typical combination of probes can be selected for these mutations, thereby achieving efficient detection.
Therefore, the inventors have screened the designed probes and found that the combination of some probes can realize effective detection. Thus, in one embodiment, the probe set comprises SEQ ID NO: 1-16.
In addition, for 6 genes of specific fusion breakpoint regions, namely ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3, the inventor carries out 3-fold high-abundance probe coverage on the genes, so that known hot spot fusion variation and unknown fusion variation can be detected more sensitively (0.5%).
Thus, in one embodiment, a probe set of the invention further comprises SEQ ID NO: 17-28.
SEQ ID NO:1-16 and SEQ ID NO: the sequences of 17-28 are shown in the following table.
In addition to the targeted drug-related genes described above, the present invention also relates to other targeted drug-related genes, aiming to more effectively screen out possible gene mutations and thus provide guidance for drug administration.
Thus, in one embodiment, the targeted drug-associated genes further comprise: AKT1, CDK4, FGFR2, MAP2K2, CDK6, FGFR3, PDGFRA, SMARCA4, APC, CDKN2A, FLT3, MLH1, PIK3CA, SMO, AR, CTNNB1, HRAS, MSH2, PMS2, SRC, ATM, DDR2, IDH1, MSH6, PTCH1, STK11, BCL2L11(BIM), IDH2, MTOR, PTEN, TP53, ERBB2, JAK2, NF1, PTPN11, TSC 11, BRCA 11, ESR 11, KIT, NRAS, RAF 11, TSC 11, BRCA 11, FBXW 11, RB, nd 11, VHL, cc3672, FGFR 11, MAP 2K.
The invention relates to a target medication related gene and a chemotherapy medication gene. Specifically, in one embodiment, the probe set further comprises a probe for a chemotherapy drug-related gene comprising: XRCC1, XPC, WT1, UMPS, UGT1A1, TYMS, TP53, STMN1, SOD2, SLIT1, SLC29A1, SLC28A3, SEMA3C, SELE, RRM1, PTGS2, NQO1, NLGN1, MTHFR, LTA, HTR1E, GSTP1, GSTO1, GGH, ESR2, ESR1, ERCC2, ERCC1, DYNC2H1, DPYD, DHFR, CYP3A4, CYP2D6, CYP19A1, COLEC10, CEP72, CDA, CBR3, C8orf34, AREG, ABCG 387 2, ABCC11, ABCB 1.
The design of the probe aiming at the chemotherapy drug related gene is based on databases such as Pharmgkb, Pubmed, FDA and the like and related documents and mechanisms, covers the current main chemotherapy drugs such as cisplatin, carboplatin, paclitaxel, docetaxel, vincristine, cyclophosphamide, epirubicin, other anthracyclines, gemcitabine, methotrexate, etoposide and the like, and detects 47 sites in total.
In a second aspect, the present invention provides a gene chip for simultaneously detecting a plurality of gene mutation types, the gene chip comprising the probe set of the first aspect of the present invention.
In a third aspect, the present invention provides a method for detecting multiple types of gene mutations, the method comprising the steps of:
1) designing a probe: designing and synthesizing a probe set according to the first aspect of the invention;
2) DNA extraction and disruption: extracting DNA of a sample to be detected and breaking the DNA into DNA fragments of 200-250 bp;
3) library construction: constructing a sample library using the disrupted DNA;
4) and (3) hybridization and capture: contacting the sample library of step 3) with the probe set of step 1) for hybrid capture;
5) and (3) machine sequencing: sequencing the captured sequence obtained in step 4) to generate sequencing data;
6) information analysis: analyzing and annotating gene mutation information of the sequencing data obtained in the step 5).
As described above, the probe design is based on databases such as TCGA, ICGC, COSMIC (for drug targeting related genes), Pharmgkb, Pubmed, FDA (for chemotherapy related genes), and related literature references. After the probe is designed, the relevant synthesis companies such as IDT or Roche are entrusted to complete the synthesis.
The DNA may be extracted from a suitable source. For example, in one embodiment, the extract can be extracted from paraffin-embedded tissue, paraffin sections, fresh pathological tissue, plasma, pleural fluid, ascites, cerebrospinal fluid, and other body fluid samples, but is not limited thereto. Any suitable sample may be used in the present invention.
The breaking of the DNA can be performed, for example, with an ultrasonic DNA breaking instrument. Thus, the DNA can be broken into 200-250bp DNA fragments.
It will be appreciated by those skilled in the art that one or more additional steps, such as fragment purification, library purification, amplification of captured products, etc., may be additionally introduced as desired in addition to the specific steps listed above.
In a fourth aspect, the present invention provides a kit for simultaneously detecting a plurality of gene mutation types, the kit comprising the probe set of the first aspect of the present invention or the gene chip of the second aspect of the present invention.
It will be appreciated that the kit may contain, in addition to the probe set or gene chip of the present invention, other reagents useful for detecting gene mutations.
For example, in one embodiment, the kit may further comprise: (1) DNA extraction reagents, such as reagents suitable for tumor cfDNA, FFPE tissue extraction; (2) a library-building agent; (3) primers and linkers, depending on the requirements of the sequencing platform, such as the Illumina platform or the cissus sequencing platform; (4) a nucleic acid purification reagent; (5) positive quality control material and negative quality control material.
The kit can effectively meet the individual medication guidance requirement of the tumor.
In a fifth aspect, the present invention provides the use of a probe set according to the first aspect of the present invention or a gene chip according to the second aspect of the present invention in the preparation of a detection reagent for simultaneously detecting one or more types of gene mutations.
As described above, the present invention can detect mutations in up to 102 genes at a time, thereby finding known and/or unknown mutations; the invention can detect related rare hotspot variation, namely 14 exon skipping mutation of MET gene, BCL2L11(BIM)2 intron deletion polymorphism related region and NTRK1/2/3 hotspot fusion mutation at one time; because the abundance coverage of the probes is carried out three times for the genes ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 of 6 specific fusion breakpoint regions, the invention can detect the known hot spot fusion and unknown fusion variation thereof more sensitively (0.5 percent).
The invention will now be further described by way of the following examples. The test methods used in the following examples are conventional methods unless otherwise specified; materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Examples
DNA extraction and disruption
Taking 10-20 Tissue slices of 1 test paraffin-embedded case Tissue, extracting DNA of the paraffin-embedded case Tissue sample according to the instruction of a QIAamp DNA FFPE Tissue Kit (Qiagen) extraction Kit, and then quantifying by using the Qubit, wherein the Tissue DNA is required to be at least more than 100 ng. And breaking the extracted tissue DNA into DNA fragments of 200bp-250bp by using an ultrasonic DNA breaking instrument, and constructing a sample library according to a library construction kit.
2. Library construction
2.1 end repair/dA Tail addition
In a sterile 1.5ml PCR tube, the end repair and addition "a" reactions were performed according to the following table configuration:
gently pipetting or shaking the mixture by using a pipettor, centrifuging the reaction solution to the bottom of the tube by short-time centrifugation, and then putting the tube into a PCR instrument for processing according to the following procedures: 20 minutes at 30 ℃ and 20 minutes at 70 ℃.
2.2 Joint connection
Based on the product of the previous step, a specific MGISEQ2000 linker was attached according to the following table configuration.
Gently pipetting or shaking the mixture by using a pipettor, centrifuging the reaction solution to the bottom of the tube by short-time centrifugation, and then putting the tube into a PCR instrument for processing according to the following procedures: 15 minutes at 20 ℃.
2.3 magnetic bead purification of ligation products
And (3) carrying out fragment sorting and purification on the product obtained in the step 2.2, wherein the specific operation steps are as follows:
1) preparation work: taking the DNA Selection Beads magnetic Beads out of the refrigerator, and balancing at room temperature for at least 30 minutes; preparing 80% ethanol.
2) The beads were mixed with 80% ethanol and vortexed or the beads were inverted sufficiently to ensure adequate mixing.
3) 60 μ L of DNA Selection Beads (0.6X, Beads: DNA ═ 0.6: 1) were pipetted into the adaptor ligation and incubated for 5 min at room temperature.
4) The PCR tube was briefly centrifuged and placed in a magnetic rack to separate the beads and liquid, and after the solution cleared (about 5 minutes), the supernatant was carefully removed.
5) The PCR tube was kept in the magnetic rack all the time, 200. mu.L of freshly prepared 80% ethanol was added to rinse the beads, and after incubation at room temperature for 30 seconds, the supernatant was carefully removed.
6) Repeat step 5) for a total of two rinses.
7) The PCR tube was kept in the magnetic stand all the time, and the beads were air dried with the lid open until cracking had just occurred (no more than 5 minutes).
8) The PCR tube was removed from the magnetic stand and 21. mu.L ddH was added2And O, vortexing or gently beating by using a pipette until the mixture is fully mixed, and standing for 5 minutes at room temperature.
9) The PCR tube was briefly centrifuged and placed in a magnetic stand and left to stand, after the solution cleared (about 5 minutes), 20. mu.L of the supernatant was carefully removed to a new PCR tube, and the beads were removed.
2.4 library amplification and purification
In a sterile 0.2ml PCR tube, a PCR reaction system is configured according to the following table, and PCR amplification enrichment is carried out on the joint connection product.
Gently blowing or shaking and mixing uniformly by using a pipettor, centrifuging the reaction solution for a short time to the bottom of the tube, and then putting the reaction solution into a PCR instrument for PCR, wherein the PCR reaction conditions are as follows:
the amplified product was subjected to fragment sorting and purification using DNA Selection Beads (0.9 ×, Beads: DNA ═ 0.9: 1). The purified product needs to be subjected to Qubit-BR quantification and 2100 quality control. Generally, a qualified library product requires a concentration greater than 20 ng/. mu.L, and a major peak of the target fragment of about 380 bp.
3. Enrichment of target sequences and sequencing on machine
3.1 after the quality control of the amplified library is qualified, hybridization capture is performed by using the probe set designed by the invention, referring to the instruction provided by the chip manufacturer (IDT). Finally, elution and redissolution of 21. mu.L ddH2And (4) hybridizing an O band to elute the magnetic beads.
3.2 amplification of hybrid Capture products
3.3 removing the magnetic beads in the previous step, then purifying the magnetic beads, and finally redissolving 25 μ L of ddH2And O, performing QC and operation.
3.4 performing on-machine sequencing on PE150 by using a MGISEQ2000 sequencer, and performing on-machine sequencing on sequencing experiment operation according to an operation instruction provided by a manufacturer.
4. Information analysis and result sorting
And after the data is downloaded, splitting a detection sample based on the barcode sequence, and simultaneously deleting low-quality data. The specific parameters are as follows: filtering out fragments with sequence head-to-tail quality values below 20; discarding short sequences lower than 40 bp; filtering the N base fragment and the adaptor sequence fragment with the ratio of more than 30 percent, and the like.
According to the position form (UID) of the template fragment, performing clustering marking and replication, simultaneously correcting and modifying the base quality value of an error base introduced by sequencing through the clustering condition, then performing re-alignment by using BWAmen, and performing alignment and replication by using GATK.
Carrying out call homogeneous SNV mutation by using mutect, varScan and somVar processes; performing variation by using gatk, varScan and somVar flow call homogeneous InDel; call CNV mutation is carried out by using a contra. py procedure; finally annotating the function of variation, the number of reads supported, the variation frequency, the amino acid variation, variation labels in Cosmic and the like by using the call SV in the somVar process.
The obtained variation result needs to be filtered based on relevant conditions so as to obtain the finally meaningful relevant mutation, and specific criteria are as follows: a. filtering out mutations that are not in the exon (exonic) region, splicing (splicing) region, exon and splicing region; b. filtering out synonymous mutations; c. filtering out variations with quality values below 30 in the repeat region; d. polymorphic mutations greater than 0.01 in the 1000G, exac, esp6500 database were filtered out.
5. And (3) analyzing a detection result:
5.1 Probe Performance evaluation (QC):
typically, a 30% coverage X of greater than 90% indicates good coverage. The detection result of the invention reaches 96.07 percent, which shows that the target interval of the detection is effectively covered.
Generally, the higher the capture efficiency of the probe, the better the specificity of the probe, and the more effective the cost of sequencing can be reduced. The capture efficiency of the invention reaches 65.47%, which is 50% higher than that of most organizations in the industry. This indicates good probe specificity.
5.2 mutation detection results
The results of detecting 3 mutations of the target genes are completely consistent with the results of known mutation types and frequencies, the details are shown in table 3, and the chemotherapy 47-site base types are also completely consistent with the known base types.
TABLE 3 details of the results of the Targeted Gene variations
5.3 interpretation of results
Based on the variation of the target gene EGFR L858R & E746A 750del, the patient is predicted to be sensitive to EGFR-TKIs medicaments, such as erlotinib, oxitinib, dacomitinib, gefitinib, erlotinib and afatinib. Based on the ALK fusion mutation of the target gene, the patient can be expected to use ALK inhibitors such as crizotinib, idetinib, ceritinib, bugatitinib and loratinib.
Based on the information of 47 chemotherapy detection sites, the calculation shows that the patients have better curative effects on the pyrimidine analogues of capecitabine, fluorouracil, tegafur, gemcitabine and raltitrexed, but the specific medication also needs to be combined with clinical caution.
Sequence listing
<110> Wuhan Honghong health Gene diagnostic technique Co Ltd
<120> Probe set for simultaneously detecting multiple gene mutation types, Gene chip and application thereof
<130> CF200420S
<160> 28
<170> SIPOSequenceListing 1.0
<210> 1
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gaaacatcct ggtagctgag gggcggaaga tgaagatttc ggatttcggc ttgtcccgag 60
atgtttatga agaggattcc tacgtgaaga ggagccaggt 100
<210> 2
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gttaggtggg acagtacagc ttccctccag ccccaggtta cccctgtcgt gtggctcctt 60
ctttgctata ggattattct ttttggtggg tttctctgta 100
<210> 3
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ggagaatagc aggtgagtga gttcccctct cgccgctcca gcatcatggg gacctgacaa 60
agtcccactc tcccctgtga tctttgcagc cagcctcgca 100
<210> 4
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ccaaacaacg ctattaatca gacccatctc catatccact gtgagtgaga caggcatagt 60
tcaggccttc aggcttgcca gaagggcagt aagccacttg 100
<210> 5
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ttggtgtaca gaaaaagaga ttaatggtta atgggcagtc ttcctctata tttctctatt 60
tcaatcccta ctccaggttc cataccttcc aggtcatcaa 100
<210> 6
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
gcagtaaggg agtgagtggg caactcggcg catgaaggag gtactcctca ttttcgttct 60
ctctctctgt gccccagccc gttggcagac ccggatcatt 100
<210> 7
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gacaccatgc agttgcgggc tgctagatct cggtgcacaa acttgttggc agcaaggtag 60
gccatgccgt ctgcaatctc accagccatt tggatcattt 100
<210> 8
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
acgcaactgt ctagtgggcc agggactggt ggtcaagatt ggtgattttg gcatgagcag 60
ggatatctac agcaccgact attaccgtgt aagggtcctt 100
<210> 9
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
gctgttaatg ttttttcccc ccttgtgaat gttttctaac tttgtcttgg taattgcaat 60
ttaactaggt gcggtggcta ctaaagttcg aaggcacgat 100
<210> 10
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
atagtccccc ctacaacata ctgtcatact gctgggtttt catgggtagg aaagcttgtc 60
ctgaccccag cagcaaagag gtggcaggtc gctaatgaat 100
<210> 11
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
caaatgaagt ctgaaaatga ctatgccagt caacacactc ctcttgacca agaagtgact 60
caccccaaaa gtgtcttctt ctggtttgtg ggtcacagtg 100
<210> 12
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
ggactctgga tcccagaagg tgagaaagtt aaaattcccg tcgctatcaa ggaattaaga 60
gaagcaacat ctccgaaagc caacaaggaa atcctcgatg 100
<210> 13
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
atgcccttcg gctgcctcct ggactatgtc cgggaacaca aagacaatat tggctcccag 60
tacctgctca actggtgtgt gcagatcgca aaggtaatca 100
<210> 14
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
attttgggct ggccaaactg ctgggtgcgg aagagaaaga ataccatgca gaaggaggca 60
aagtaaggag gtggctttag gtcagccagc attttcctga 100
<210> 15
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
tccacaaaat ggatccagac aactgttcaa actgatggga cccactccat cgagatttca 60
ctgtagctag accaaaatca cctattttta ctgtgaggtc 100
<210> 16
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
ctgaattagc tgtatcgtca aggcactctt gcctacgcca ccagctccaa ctaccacaag 60
tttatattca gtcattttca gcaggcctta taataaaaat 100
<210> 17
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
aatgcccccc tccctcgagc cctcccttcc acatggattg aaaacaaact ctatggtaga 60
atttcccatg catttactag attctagcac cgctgtcccc 100
<210> 18
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
tgctgcattt cagagaacgc ctccccgagt gagctgcgag acctgctgtc agagttcaac 60
gtcctgaagc aggtcaacca cccacatgtc atcaaattgt 100
<210> 19
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
aagaaaaact gcttagtaac tagcagaagt gttcctaaaa gagtcataca caggcccagg 60
gcagttcttg ggtgggtcca tccggcctcc actggtgaca 100
<210> 20
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
cagcaccgtc ccgtggtcac agaagcagat gaccttgtgg ctttcagggt ccatgtgaca 60
ttcgtctacc tcacagtgac tgcagtttag ataatgctta 100
<210> 21
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
acttctccaa aggctccact tcccagcaag agacgcagag tcagtttttc ccgagggaag 60
gcaggaagat tttcaatctc ctcttgggtt ggaagagtac 100
<210> 22
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
ttggcttgtg gcttgattgc aaagtccttt aacgtgcaac tctccacaat acgcacagct 60
tctgcacacc ggccagatgg tacaggaagg tctgctctat 100
<210> 23
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 23
tgctttctct cctccctcct gctgcagtct ccttctcgcc ggtgggtgag tagcccaagg 60
tggagggcag gttctgcctg gtctctggag ctgaggctgg 100
<210> 24
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 24
cccccacggc tcctcgggac tgcgatgcac ccgggatggg gccctggata gcctccacca 60
cctgcccggc gcagagaacc tgactgagct gtgagtgtcc 100
<210> 25
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 25
cttcagcgac agtgtaagga aggaaggggg aggtgactta aggggtgagg gtgctgtggg 60
gagggagaat gttgagaatg aagtggtgtt tctatttatg 100
<210> 26
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 26
aaggacagtg ttgaccacct ccggtttcta cttctctttc gaagtttatt ttatgttttg 60
ttgtggtttt cagatttctc atggtttgga tttgggaaag 100
<210> 27
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 27
acctgcacac accaagagag acgcaggacc tggtgacgtc acatccggcc agtttccagc 60
cctgtccaca gacaaccccc aactactgtt cccatcacaa 100
<210> 28
<211> 100
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 28
gagagcaatg ggagattaaa acagtatctt ttgatcaaaa gcagtaatgt ttccccccat 60
gacgcccttg aaaatgaaac tcccacctta cccttcattc 100
Claims (10)
1. A probe set for simultaneously detecting multiple gene mutation types, the probe set comprising probes for targeted medication-related genes, wherein the targeted medication-related genes comprise EGFR, BRAF, KRAS, HER2, MET, ALK, RET, ROS1, NTRK1, NTRK2, NTRK3, and gene mutations thereon comprise:
1) for the EGFR gene: g719, A698, V765, F712, L703, A702, G724, E709, S720, E709, S752_ I759del, L747_ S752del, L747_ T751del, E746_ A750del, E746_ S752> 747_ E749del, L747_ T751> 746_ E749del, K745_ E749del, L747_ T751del, S752_ I759del, T751_ I759del, L747_ P753> 746_ S752del, E _ T751del, E746_ T871 > 871 _ S752> 747_ T751> 747_ A750> 747_ P753> 797 _ T774, E _ D793, G793D 793, D79, D769, D770, GI 793, 793D 793, D793D 769, D770, 3D 79, 3D 793, 3D 793, 3D 7944, 3D 793, 3D 7944, 3D 770, 3D 7944, 3D 7944, 3D 7678, 3D 7944, 3D 793, 3D 79;
2) for the BRAF gene: a598_ T599insV, a598V, D594G, D594N, D594V, E586E, E586K, F583F, F595L, F595S, G596D, G596R, G606E, H608R, I582M, I592M, I592V, K601V, L584V, L597V, N593672, P213V, S605V, S V, T599_ V600insT, T599_ V600insTT, T599V, V600_ K601> V, V600, V V, V600V V, V36600V V, V;
3) for the KRAS gene: g _ a11insG, G _ G13insG, L19, G13, V14, G12, L19, G _ V14insG, G12, V8, a11, G12, G13, G15, a18, Q22, G13, a _ G12insGA, a59, Q61, T58, a146, K117;
4) for the HER2 gene: D769H, L755S, I767M, L755P, G776> VC, V777L, G776V, G778_ S779insG, V777A, V842I, H878Y;
5) for the MET gene: exon skipping mutations of E168D, T1010I, H1112Y, H1124D, H1112L, L1130L, N1118Y, H1112R, M1268T, Y1248C, Y1253D, 14;
6) for the ALK gene: EML 4-ALK;
7) for the RET gene: NCOA4-RET, PRKAR1A-RET, PCM1-RET, KTN1-RET, KIF5B-RET, HOOK3-RET, GOLGA5-RET, CCDC 6-RET;
8) for the ROS1 gene: TPM3-ROS1, SLC34A2-ROS1, SDC4-ROS1, LRIG3-ROS1, GOPC-ROS1, EZR-ROS1, CD74-ROS 1;
9) for NTRK1/2/3 genes: TPM3-NTRK1, LMNA-NTRK1, NACC2-NTRK2, QKI-NTRK2, ETV6-NTRK 3.
2. The probe set of claim 1, comprising the probe sequences set forth in SEQ ID NOS 1-16.
3. The probe set according to claim 1 or 2, further comprising the probe sequences shown in SEQ ID NO 17-28.
4. The panel of claim 1-3, wherein said targeted drug-associated gene further comprises: AKT1, CDK4, FGFR2, MAP2K2, CDK6, FGFR3, PDGFRA, SMARCA4, APC, CDKN2A, FLT3, MLH1, PIK3CA, SMO, AR, CTNNB1, HRAS, MSH2, PMS2, SRC, ATM, DDR2, IDH1, MSH6, PTCH1, STK11, BCL2L11(BIM), IDH2, MTOR, PTEN, TP53, ERBB2, JAK2, NF1, PTPN11, TSC 11, BRCA 11, ESR 11, KIT, NRAS, RAF 11, TSC 11, BRCA 11, FBXW 11, RB, nd 11, VHL, cc3672, FGFR 11, MAP 2K.
5. The set of probes of any of claims 1-4, wherein said set of probes further comprises probes for chemotherapeutic drug-related genes comprising:
XRCC1、XPC、WT1、UMPS、UGT1A1、TYMS、TP53、STMN1、SOD2、SLIT1、SLC29A1、SLC28A3、SEMA3C、SELE、RRM1、PTGS2、NQO1、NLGN1、MTHFR、LTA、HTR1E、GSTP1、GSTO1、GGH、ESR2、ESR1、ERCC2、ERCC1、DYNC2H1、DPYD、DHFR、CYP3A4、CYP2D6、CYP19A1、COLEC10、CEP72、CDA、CBR3、C8orf34、AREG、ABCG2、ABCC11、ABCB1。
6. a gene chip for simultaneously detecting a plurality of gene mutation types, the gene chip comprising the probe set of any one of claims 1 to 5.
7. A method for detecting multiple gene mutation types, the method comprising the steps of:
1) designing a probe: designing and synthesizing a set of probes according to any one of claims 1-5;
2) DNA extraction and disruption: extracting DNA of a sample to be detected and breaking the DNA into DNA fragments of 200-250 bp;
3) library construction: constructing a sample library using the disrupted DNA;
4) and (3) hybridization and capture: contacting the sample library of step 3) with the probe set of step 1) for hybrid capture;
5) and (3) machine sequencing: sequencing the captured sequence obtained in step 4) to generate sequencing data;
6) information analysis: analyzing and annotating gene mutation information of the sequencing data obtained in the step 5).
8. The method of claim 7, wherein the test sample comprises a body fluid sample such as paraffin-embedded tissue, paraffin sections, fresh pathological tissue, plasma, pleural fluid, ascites, cerebrospinal fluid, and the like.
9. A kit for simultaneously detecting a plurality of gene mutation types, the kit comprising the probe set of any one of claims 1 to 5 or the gene chip of claim 6.
10. Use of a set of probes according to any one of claims 1 to 5 or a gene chip according to claim 6 for the preparation of a detection reagent for the simultaneous detection of one or more types of genetic mutations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010991893.6A CN112029865A (en) | 2020-09-18 | 2020-09-18 | Probe group and gene chip for simultaneously detecting multiple gene mutation types and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010991893.6A CN112029865A (en) | 2020-09-18 | 2020-09-18 | Probe group and gene chip for simultaneously detecting multiple gene mutation types and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112029865A true CN112029865A (en) | 2020-12-04 |
Family
ID=73574085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010991893.6A Pending CN112029865A (en) | 2020-09-18 | 2020-09-18 | Probe group and gene chip for simultaneously detecting multiple gene mutation types and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112029865A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113249444A (en) * | 2021-05-17 | 2021-08-13 | 苏州吉因加生物医学工程有限公司 | DNA probe library for hybridization with FGFR1, 2 or 3 gene and application |
CN114606318A (en) * | 2022-03-25 | 2022-06-10 | 杭州瑞普基因科技有限公司 | Application of probe set in detecting BIM gene deletion polymorphism |
CN116397027A (en) * | 2022-12-29 | 2023-07-07 | 北京阅微基因技术股份有限公司 | Composite amplification system and kit for combined detection of KRAS/NRAS/BRAF genotyping |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104894269A (en) * | 2015-06-09 | 2015-09-09 | 广东省人民医院 | Lung cancer gene spectrum detection method and kit based on Mass ARRAY platform Iplex analysis and application of kit |
CN106480205A (en) * | 2016-11-11 | 2017-03-08 | 北京吉因加科技有限公司 | For detecting combined sequence and the probe of various mutations type simultaneously |
CN107312822A (en) * | 2016-04-26 | 2017-11-03 | 厦门飞朔生物技术有限公司 | A kind of construction method in oncogene variation library detected for high-flux sequence and its application |
US20180045727A1 (en) * | 2015-03-03 | 2018-02-15 | Caris Mpi, Inc. | Molecular profiling for cancer |
CN110527710A (en) * | 2019-10-30 | 2019-12-03 | 上海润安医学科技有限公司 | A kind of primer, probe and kit being mutated for detecting NTRK Gene Fusion |
CN110904235A (en) * | 2019-12-20 | 2020-03-24 | 深圳市新合生物医疗科技有限公司 | Gene panel for detecting tumor targeted drug related gene mutation, method, application and kit |
-
2020
- 2020-09-18 CN CN202010991893.6A patent/CN112029865A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180045727A1 (en) * | 2015-03-03 | 2018-02-15 | Caris Mpi, Inc. | Molecular profiling for cancer |
CN104894269A (en) * | 2015-06-09 | 2015-09-09 | 广东省人民医院 | Lung cancer gene spectrum detection method and kit based on Mass ARRAY platform Iplex analysis and application of kit |
CN107312822A (en) * | 2016-04-26 | 2017-11-03 | 厦门飞朔生物技术有限公司 | A kind of construction method in oncogene variation library detected for high-flux sequence and its application |
CN106480205A (en) * | 2016-11-11 | 2017-03-08 | 北京吉因加科技有限公司 | For detecting combined sequence and the probe of various mutations type simultaneously |
CN110527710A (en) * | 2019-10-30 | 2019-12-03 | 上海润安医学科技有限公司 | A kind of primer, probe and kit being mutated for detecting NTRK Gene Fusion |
CN110904235A (en) * | 2019-12-20 | 2020-03-24 | 深圳市新合生物医疗科技有限公司 | Gene panel for detecting tumor targeted drug related gene mutation, method, application and kit |
Non-Patent Citations (1)
Title |
---|
徐笑红,等: "基因芯片检测肿瘤病人多药耐药基因1多态性方法的建立", 《中国卫生检验杂志》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113249444A (en) * | 2021-05-17 | 2021-08-13 | 苏州吉因加生物医学工程有限公司 | DNA probe library for hybridization with FGFR1, 2 or 3 gene and application |
CN113249444B (en) * | 2021-05-17 | 2023-10-13 | 苏州吉因加生物医学工程有限公司 | DNA probe library for hybridization with FGFR1, 2 or 3 genes and application thereof |
CN114606318A (en) * | 2022-03-25 | 2022-06-10 | 杭州瑞普基因科技有限公司 | Application of probe set in detecting BIM gene deletion polymorphism |
CN114606318B (en) * | 2022-03-25 | 2023-12-01 | 杭州瑞普基因科技有限公司 | Application of probe set in detecting BIM gene deletion polymorphism |
CN116397027A (en) * | 2022-12-29 | 2023-07-07 | 北京阅微基因技术股份有限公司 | Composite amplification system and kit for combined detection of KRAS/NRAS/BRAF genotyping |
CN116397027B (en) * | 2022-12-29 | 2023-10-10 | 北京阅微基因技术股份有限公司 | Composite amplification system and kit for combined detection of KRAS/NRAS/BRAF genotyping |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108424955B (en) | High-throughput sequencing method for detecting multiple variant genes and application thereof | |
Denis et al. | Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery | |
CN105624309B (en) | Primer, probe and kit for detecting EGFR and/or K-ras gene mutation | |
EP2986736B1 (en) | Gene fusions and gene variants associated with cancer | |
Xia et al. | Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer | |
CN112029865A (en) | Probe group and gene chip for simultaneously detecting multiple gene mutation types and application thereof | |
CN104630375B (en) | Cancer gene is mutated and gene magnification detection | |
Jia et al. | Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases | |
JP2020530290A (en) | Methods and Substances for Assessing and Treating Cancer | |
EP3122901B1 (en) | Gene fusions and gene variants associated with cancer | |
CN108374046B (en) | Tumor cell microsatellite unstable state detection system | |
McCall et al. | False positives in multiplex PCR-based next-generation sequencing have unique signatures | |
Misyura et al. | Comparison of next-generation sequencing panels and platforms for detection and verification of somatic tumor variants for clinical diagnostics | |
CN107475370A (en) | Gene group and kit and diagnostic method for pulmonary cancer diagnosis | |
CN104450948B (en) | Method for detecting cancer, kit and its application | |
CN111826447B (en) | Method for detecting tumor mutation load and prediction model | |
JP2021516962A (en) | Improved variant detection | |
Hájková et al. | Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico‑pathological and molecular (next generation sequencing) study of 22 cases | |
US20230203590A1 (en) | Methods and means for diagnosing lung cancer | |
CN111424087A (en) | Detection Panel for pan-cancer species detection or targeted drug application based on next-generation sequencing, kit and application | |
CN114480660A (en) | Gene Panel for detecting pan-cancer species, probe and application | |
Santini et al. | Network approach in liquidomics landscape | |
CN111154872A (en) | Probe and kit for detecting lung cancer driving gene mutation | |
CA3159505A1 (en) | Methods and compositions for analyses of cancer | |
Mendez et al. | Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201204 |
|
WD01 | Invention patent application deemed withdrawn after publication |